Report Code : A05105
Rise in the demand for the better healthcare facilities, increasing investment by healthcare companies, rise in the chronic disease around the globe, high prevalence of the heart related diseases and rapid technological advancements in the healthcare sector are some factors that boost the growth of the market.
Onkar Sumant - Manager
Life Sciences at Allied Market Research
According to a new report published by Allied Market Research, titled, “Pulmonary Arterial Hypertension Treatment Market," The pulmonary arterial hypertension treatment market size was valued at $7,177.81 million in 2021, and is projected to reach $11,968.60 million by 2031, growing at a CAGR of 5.2% from 2021 to 2031.
The normal blood pressure of an artery is considered as 25mmHg. When the blood pressure increases above this normal range it is considered as pulmonary hypertension (PH) condition. Further, the pulmonary arterial hypertension (PAH) is a condition in which endothelial dysfunction and vascular remodeling cause obstruction to the small pulmonary arteries, which results in increased pulmonary vascular resistance and pulmonary pressures. It is characterized by narrowed and blocked arteries and capillaries. To treat such serious conditions the healthcare provider mainly prescribe drugs such as endothelin receptor antagonists (ERAs), PDE5 inhibitors, prostacyclin, and prostacyclin analogs, and sGC stimulators to treat pulmonary arterial hypertension. These drugs helps to relax the muscles in the wall of the blood vessels, or increase the blood flow through the lungs, or reverse the effects of the substance in the walls of blood vessels, which caused them to narrow in the beginning.
The key factors that drive the growth of the pulmonary arterial hypertension treatment industry include rise in prevalence of pulmonary arterial hypertension cases and development of advanced technologies for the treatment, and drug development, product approvals, and funding initiatives by major organizations for the research and development activities. For instance, in March 2019, Sandoz (Novartis AG) announced the use of AP-rated generic Remodulin (treprostinil) injection, offered by United Therapeutics Corporation in the U.S. which is indicated for pulmonary arterial hypertension to reduce the symptoms associated with exercise, also rise in the demand for the better healthcare facilities, increasing investment by healthcare companies, rise in the chronic disease around the globe, high prevalence of the heart related diseases and rapid technological advancements in the healthcare sector are some factors that boost the growth of the market.
In addition, the increase in geriatric population, rise in number of product launches, and the rise in number of HIV population are the drivers for the expansion of the market during the forecast period. In addition, rise in number of key strategic developments such as product launch, collaboration and acquisitions boost the growth of the pulmonary arterial hypertension treatment market size. Moreover, key players are involving in the manufacturing of innovative drugs which will provide opportunities for the growth of the pulmonary arterial hypertension treatment market during the forecast period.
pulmonary arterial hypertension treatment market analysis include drug type, on the basis of drug type, the pulmonary arterial hypertension treatment industry is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and sGC stimulators. In 2021, the prostacyclin and prostacyclin analogs segment accounted for the largest share of the market, and is expected to grow at the fastest CAGR rate during the pulmonary arterial hypertension treatment market forecast period due to increase in pulmonary arterial hypertension treatment market trends includes prevalence of pulmonary hypertension and rise in demand for prostacyclin and prostacyclin analog.
On the basis of type, it is bifurcated into branded and generic. In 2021, the branded segment accounted for the largest share of the market, owing to, increase in patients seeking branded medication treatments whereas the generics segment is the fastest growing segment during the forecast period owing to, rise in approval of generic version medications for the treatment of pulmonary.
On the basis of route of administration, the market is classified into oral, intravenous/subcutaneous, and inhalational. In 2021, the oral segment accounted for the largest share of the market, owing to its advantages such as most convenient route for medication administration, safe, and mostly preferred and is also expected to grow at the fastest rate during the forecast period.
On the basis of region, North America accounted for a majority of the pulmonary arterial hypertension treatment market share in 2021, and this is attributed to rise in number of chronic disease cases, presence of key players and advancement in healthcare in the region. whereas the Asia-Pacific is anticipated to witness lucrative growth with the highest CAGR during the forecast period, owing to increase in medical tourism, implementation of new ICT guidelines in Japan, investments, and reforms to modernize healthcare infrastructure of China, and rapid growth in healthcare industry in India.
KEY FINDINGS OF THE STUDY
Talk to David (Europe)
Talk to Sona Padman (Americas)
5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91 2066346060
Fax: +1(855) 550-5975
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com
Pulmonary Arterial Hypertension Treatment Market By Drug Type (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational): Global Opportunity Analysis and Industry Forecast, 2021 - 2031
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Buy Full Version
"Pulmonary Arterial Hypertension Treatment Market"
Purchase Enquiry
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers